Dioxidine
PreclinicalSmall molecule
Dioxidine is one of 4 small molecule programs targeting Kidney Stones. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Kidney Stones
#DrugCompanyPhaseTrials
1Thalitone
Jazz PharmaceuticalsApproved
Potassium Iodide
MMeda Pharmaceuticals
Approved
Alka-Seltzer
AAbbott
Phase 2
Dioxidine
WWest Kazakhstan Marat Ospanov Medical University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dioxidine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details